Literature DB >> 9153566

Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years.

J M Kremer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9153566     DOI： 10.1002/art.1780400533

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  17 in total

Review 1.  "Stepping-up" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate.

Authors:  M C Hochberg; J K Tracy; R H Flores
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

Review 2.  Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis.

Authors:  M C Hochberg; J K Tracy; M Hawkins-Holt; R H Flores
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 3.  Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins.

Authors:  Radjesh J Bisoendial; Erik S G Stroes; John J P Kastelein; Paul Peter Tak
Journal:  Nat Rev Rheumatol       Date:  2010-02-09       Impact factor: 20.543

4.  When should we use parenteral methotrexate?

Authors:  Hayley Mainman; Emma McClaren; Carol Heycock; Vadivelu Saravanan; Jennifer Hamilton; Clive Kelly
Journal:  Clin Rheumatol       Date:  2010-06-11       Impact factor: 2.980

Review 5.  Early rheumatoid arthritis: pitfalls in diagnosis and review of recent clinical trials.

Authors:  Amy C Cannella; James R O'Dell
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 6.  Optimising low-dose methotrexate for rheumatoid arthritis-A review.

Authors:  Catherine J Lucas; Simon B Dimmitt; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2019-08-09       Impact factor: 4.335

7.  Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis.

Authors:  Gloris Sánchez; Julio S Castro; Soham Al Snih; Luísa Pérez Blanco; María H Esteva; Ernesto García Macgregor; Marielena González; Ysabel Granados; Francisco Marín; Alexis Rosas; Antonio Tristano; Esther Chirinos; Luís Mundaraín; Gilberto Sanoja; Guisela Zambrano-Marín; Martín A Rodríguez
Journal:  Rheumatol Int       Date:  2006-11-11       Impact factor: 2.631

8.  Reversible Epstein-Barr virus-negative lymphadenopathy and bone marrow involved by Hodgkin's lymphoma in a rheumatoid arthritis patient undergoing long-term treatment with low-dose methotrexate: a case report and review of the literature.

Authors:  Annika M Svensson; Erica R Jacobson; David Ospina; Barbara H Tindle
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

Review 9.  Methotrexate in rheumatoid arthritis: a quarter century of development.

Authors:  Michael E Weinblatt
Journal:  Trans Am Clin Climatol Assoc       Date:  2013

10.  Patient preferences for treatment of rheumatoid arthritis.

Authors:  L Fraenkel; S T Bogardus; J Concato; D T Felson; D R Wittink
Journal:  Ann Rheum Dis       Date:  2004-03-05       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.